Market Overview

The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Ocular Therapeutix, Inc.


The Klein Law Firm announces the commencement of an investigation of
Ocular Therapeutix, Inc. (NASDAQ:OCUL) concerning possible violations of
federal securities laws.

On May 5, 2017, Ocular Therapeutix disclosed that the U.S. Food and Drug
Administration had found minor issues at its manufacturing plant.
However, on July 6, 2017, an article published by Seeking Alpha claimed
that Ocular Therapeutix's management had been misleading investors about
manufacturing issues. One of the claims made by the article is that more
than 50% of lots manufactured by Ocular Therapeutix contain bad product.
Following this news, the price of Ocular Therapeutix shares fell $0.68
per share or over 6% to close at $9.50 per share on July 6, 2017.

If you suffered a loss in Ocular Therapeutix and wish to obtain
additional information, please contact Joseph Klein, Esq. by telephone
at 212-616-4899 or visit

Joseph Klein, Esq. is an experienced attorney and has also practiced as
a Certified Public Accountant. Mr. Klein represents investors and
participates in securities litigations involving financial fraud
throughout the nation. Attorney advertising. Prior results do not
guarantee similar outcomes.

View Comments and Join the Discussion!

Partner Center